Exosomal microRNA-21-5p from gastric cancer cells promotes angiogenesis by targeting LEMD3 in human endothelial cells DOI Creative Commons

Tianbao Zhou,

Ping Lu

ONCOLOGIE, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 18, 2024

Abstract Objectives The effect of exosome-derived miR-21-5p from gastric cancer (GC) on angiogenesis remains unclear. This study aims to examine the angiogenic impact GC miR-21-5p. Methods Exosomes were isolated cells and co-cultured with human umbilical vein endothelial (HUVECs). levels in HUVECs measured by qPCR. Flow cytometry was used assess apoptosis, Cell Counting Kit-8 cell growth. Bioinformatics analysis identify target genes, which then verified dual-luciferase gene reporter experiments. qPCR western blotting employed expression genes proteins, respectively. Functional rescue assays conducted verify that regulates function targeting LEM domain containing 3 (LEMD3). Additionally, migration assessed using a scratch assay. Results Co-cultivation GC-derived exosomes improved survival, decreased raised HUVECs. Increases vascular growth factor A (VEGFA) TGF-β/Smad signaling pathway seen. It shown targets LEMD3. biological effects lessened when inhibited, or LEMD3 overexpressed. Conclusions By LEMD3, stimulates triggering cascade upregulating VEGFA expression. leads increased proliferation, HUVECs, underscoring potential this therapy.

Language: Английский

Tailoring traditional Chinese medicine in cancer therapy DOI Creative Commons

Shuiquan Li,

Xi Chen, Hui Shi

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 21, 2025

Language: Английский

Citations

5
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence DOI Creative Commons
Muhammad Tufail, Canhua Jiang, Ning Li

et al.

Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 11, 2025

Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.

Language: Английский

Citations

2
Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways DOI

Songyu Shen,

Yihan Hong,

Jiajun Huang

et al.

Cytokine & Growth Factor Reviews, Journal Year: 2024, Volume and Issue: 79, P. 16 - 28

Published: Aug. 10, 2024

Language: Английский

Citations

9
Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study DOI Creative Commons
Bin Yin, Wei Luo

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Jan. 28, 2025

The clinical benefits of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients are controversial. This study intended to evaluate the efficacy and safety these patients. In this retrospective study, 71 receiving or alone were divided into chemo group (N = 23) 48). Objective response rate (52.2% vs. 35.4%), disease control (91.3% 81.3%), surgical resection (95.7% 85.4%), R0 (87.0% 75.0%), proportion with tumor regression grade 0–1 (31.8% 17.1%) tended increase versus group, although there was no statistical significance. 48-month progression-free survival (PFS) rates 58.3% 33.4% group. overall (OS) 65.1% 46.5% respectively. PFS ascend, but OS did not vary Bevacizumab (vs. chemo) independently related longer [hazard ratio (HR) 0.263, P 0.015], (HR 0.207, 0.056) incidence 3–4 adverse events between groups (all > 0.05). Neoadjuvant achieves higher treatment some extent, tolerable patients, its application needs further verification.

Language: Английский

Citations

1
Mapping Tumor–Stroma–ECM Interactions in Spatially Advanced 3D Models of Pancreatic Cancer DOI Creative Commons

A.C. Kataki,

Priyanka Gupta, Umber Cheema

et al.

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: March 7, 2025

Bioengineering-based in vitro tumor models are increasingly important as tools for studying disease progression and therapy response many cancers, including the deadly pancreatic ductal adenocarcinoma (PDAC) that exhibits a tumor/tissue microenvironment of high cellular/biochemical complexity. Therefore, it is crucial to capture complexity enable investigation interplay between cancer cells factors such extracellular matrix (ECM) proteins or stroma cells. Using polyurethane (PU) scaffolds, we performed systematic study on how different ECM protein scaffold coatings impact long-term cell evolution scaffolds containing only (activated stellate endothelial cells). To investigate potential further changes those biomarkers due cancer-stroma interactions, mapped their expression dual/zonal consisting core periphery, spatially mimicking fibrotic/desmoplastic reaction PDAC. In our single observed coating affected spatial aggregation, deposition, biomarker upregulation cell-line-dependent manner. levels fibrosis/desmoplasia terms composition/quantity were generated depending coating. When model, linked aggressiveness/invasiveness upregulated by both compared models. Collectively, advances understanding PU scaffolds. Our findings show within bioengineered models, can stimulate PDAC develop aggressiveness/invasiveness, well fibrosis. Furthermore, highlight importance considering map invasion. work contributes design with variable, yet biomimetic, tissue-like properties microenvironment's role progression.

Language: Английский

Citations

0
Natural Products as Novel Therapeutic Agents for Triple-Negative Breast Cancer: Current Evidence, Mechanisms, Challenges, and Opportunities DOI Creative Commons

Qingzhou Li,

Zhen Ye, Guilin Wang

et al.

Molecules, Journal Year: 2025, Volume and Issue: 30(6), P. 1201 - 1201

Published: March 7, 2025

Breast cancer (BC) tops the list of causes for female fatalities globally, with elusive triple-negative breast (TNBC) constituting 10–20% all cases. Current clinical strategies combating TNBC encompass a multifaceted approach, including surgical intervention, radiation therapy, chemotherapy, and advanced targeted drugs immunotherapies. While these modalities have catalyzed significant advancements in management, lingering limitations continue to pose formidable challenges. There is an acute need novel therapeutics realm treatment. Natural products (NPs) emerged as rich reservoir pharmaceutical innovation, owing their extraordinary range structures physicochemical properties. Scholars reported diverse evidence NPs’ efficacy against TNBC. This review aims comprehensively explore bioactive constituents, specifics commonalities chemical structure, pharmacological mechanisms NPs, specifically examining roles impeding which recently garnered interest, are intriguing terms capacity combat through mechanisms, suppression tumor cell proliferation, induction apoptosis, inhibition metastasis. These natural agents primarily compounds, terpenoids, glycosides, phenolic alkaloids. An in-depth exploration has unveiled involvement key signaling pathways, transforming growth factor-beta (TGF-β), vascular endothelial factor A (VEGFA), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), Wingless/Int-1 (Wnt) /β-catenin, mitogen-activated protein (MAPK) pathways. Meanwhile, this also looks at challenges opportunities that arise from harnessing compounds influence TNBC, while outlining prospective trajectory future research field NPs.

Language: Английский

Citations

0
Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota DOI
Ali Rahimi,

Zeinab Baghernejadan,

Ali Hazrati

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 186, P. 118014 - 118014

Published: March 31, 2025

Language: Английский

Citations

0
STAT3 Signaling Pathway in Health and Disease DOI Creative Commons
Md Abdus Samad, Iftikhar Ahmad, A. M. Mahedi Hasan

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(4)

Published: March 30, 2025

ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a critical factor involved in multiple physiological pathological processes. While STAT3 plays an essential role homeostasis, its persistent activation has been implicated the pathogenesis various diseases, particularly cancer, bone‐related autoimmune disorders, inflammatory cardiovascular neurodegenerative conditions. The interleukin‐6/Janus kinase (JAK)/STAT3 signaling axis central to activation, influencing tumor microenvironment remodeling, angiogenesis, immune evasion, therapy resistance. Despite extensive research, precise mechanisms underlying dysregulated disease progression remain incompletely understood, no United States Food Drug Administration (USFDA)‐approved direct inhibitors currently exist. This review provides comprehensive evaluation STAT3's health disease, emphasizing involvement cancer stem cell maintenance, metastasis, inflammation, drug We systematically discuss therapeutic strategies, including JAK (tofacitinib, ruxolitinib), Src Homology 2 domain (S3I‐201, STATTIC), antisense oligonucleotides (AZD9150), nanomedicine‐based delivery systems, which enhance specificity bioavailability while reducing toxicity. By integrating molecular mechanisms, pathology, emerging interventions, this fills knowledge gap STAT3‐targeted therapy. Our insights into crosstalk, epigenetic regulation, resistance offer foundation for developing next‐generation with greater clinical efficacy translational potential.

Language: Английский

Citations

0
Chlorella pyrenoidosa-Based Antibiotic Liposomal Gel Promotes Wound Healing by Scavenging Biofilm and Accelerating Regeneration DOI

Yuping Sun,

Mengmeng Qiu,

Jing‐Wen Yang

et al.

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: May 9, 2025

The biofilm functions as a physical barrier for bacteria, enhancing their resistance to antibiotics and contributing recurrent infections. Therefore, the scavenging of biofilms has become an important strategy treating chronic In this study, we demonstrated that Chlorella pyrenoidosa (CP) downregulates adhesion genes Staphylococcus aureus inhibits formation. Through combination CP with antibiotic drug berberine hydrochloride (BH) stabilizers (Poloxamer 188 Poloxamer 407), developed biologically active hydrogel system, which termed BHLip@CP gel. Under laser irradiation, gel generated reactive oxygen species, assisted BH effectively inhibit formation in S. reduce production virulence factors. addition, accelerated wound healing infections by promoting angiogenesis skin regeneration. This study proposes innovative simultaneously eliminate bacterial promote via synergistic approach combines chemical photodynamic processes.

Language: Английский

Citations

0
The RNA‐Binding Proteins MCPIP2 and IGF2BP1 Competitively Modulate Breast Tumor Angiogenesis by Antagonizing VEGFA mRNA Stability and Expression DOI Creative Commons
Wenbao Lu, Hongwei Li,

Xueting Liu

et al.

The FASEB Journal, Journal Year: 2025, Volume and Issue: 39(10)

Published: May 12, 2025

ABSTRACT Tumor angiogenesis is essential for further growth and metastasis of solid tumors. However, the mechanisms underlying angiogenesis‐related gene expression have yet to be clarified. Here, we discovered RNA‐binding proteins monocyte chemotactic protein‐induced protein 2 (MCPIP2) insulin‐like factor mRNA‐binding 1 (IGF2BP1) function as a pair antagonists that modulate breast tumor by competitively regulating mRNA stability proangiogenic transcripts, including vascular endothelial A ( VEGFA ), Erb‐B2 receptor tyrosine kinase ERBB2 interleukin‐8 IL8 C‐X‐C motif chemokine ligand CXCL1 ephrin A1 EFNA1 ). Mechanistically, MCPIP2 physically interacted with stem–loop structures in 3′‐untranslated region transcripts through its RNase domain destabilize their mRNAs. Ribosomal might required MCPIP2‐mediated destabilization On other hand, IGF2BP1 can stabilize mRNAs binding common RNA structures. Furthermore, found human tumors was repressed, whereas increased. Lower higher were significantly associated poor survival cancer patients, respectively. Notably, there reversed correlation relationship between MCPIP2, expression, samples. Collectively, our results elucidate novel mechanism which provides new insights into antiangiogenic therapy cancer.

Language: Английский

Citations

0